Malin Richter as Director Operations and Kristoffer Ahlerup as Director Commercial. In addition, the company has implemented several organizational changes to be able to handle the next phase of its growth journey.
Lund-based Enzymatica develops and sells health products for diseases and symptoms in the ear, nose and throat region. The company's first product is the mouth spray ColdZyme, the third largest cold medicine brand in Sweden.
Enzymatica not only has a strong presence in its home market, but has also launched ColdZyme in around 30 markets on three continents. The goal is to expand to even more geographical markets through established partners. The company's strategy is also based on developing more products and strengthening its position in existing markets.
Strategic new recruitments
At the end of last week, Enzymatica announced that it had recruited Malin Richter as Director Operations and Kristoffer Ahlerup as Director Commercial. Both will be part of Enzymatica's management team and are expected to bring significant knowledge and experience to the company, according to Claus Egstrand, COO and Senior Director Growth:
»We have so much more growth ahead of us that will require us to continuously strengthen our capabilities and resources in our organization. We are therefore very pleased with the recruitments of Malin Richter and Kristoffer Ahlerup, both with long and successful experience from the international life science industry« – Claus Egstrand, Chief Operating Officer and Senior Director Growth at Enzymatica.
Malin Richter is responsible for production.
Malin Richter took up the position of Director Operations on January 11 this year. Her areas of responsibility are production, supply and supply planning including contacts with contract manufacturers, Contract Manufacturing Organizations (CMOs)., and Design & Development (D&D).
Richter most recently comes from a position as Head of Plan for McNeil, a role that included planning, purchasing materials, and launching new products and artwork.
She has also held several management positions at pharmacy where she was responsible, among other things, for Nicorette-the range, Treo and MicrolaxFurthermore, she had the primary operational contact with Glaxo Smith Kline for the distribution of Nicorette chewing gum in the US. Malin also has extensive experience working with players in Japan, China and EMEA (Europe, Middle East and Africa).
Kristoffer Ahlerup – new commercial key person
Kristoffer Ahlerup starts as Director Commercial for Enzymatica on February 1. The position means that he will be responsible for sales and marketing, international expansion and business development.
Ahlerup has 17 years of experience in life science and consumer healthcare from large companies such as L'Oreal, Ferrosan and Reckitt BenckiserHe most recently came from a role as Brand Director for L'Oreal where he was responsible for two leading skincare brands in the Nordics.
He will primarily contribute experience in brand and product marketing, sales and key account management with a focus on brand development and business development together with retailers and distributors around the world.
Organizational changes as a result of international expansion
In addition to the recent recruitments, Enzymatica has made several organizational changes in light of its international expansion and recent successes.
Johan Lindvall, formerly Chief Technical Officer, will transition to the role of Director Global Project Management. He will have overall oversight, including resource allocation and scheduling, of Enzymatica's key projects, particularly those related to geographic expansion and new products.
Speaking of new products – Ulf Blom, one of Enzymatica's founders, will take on the new role of Director Innovation for the development of new products and indications. Blom was previously the company's Sales and Marketing Director.
Regulatory issues and quality assurance
Ann-Christine Provoost, Director of Regulatory Affairs, will expand his responsibilities to include preclinical and clinical development, reflecting the importance of regulatory issues and the updated MDR requirements. The MDR is the new regulation for medical devices that replaces the Medical Devices Directive (MDD) this year, leading to major changes and stricter requirements for many companies, including Enzymatica.
Another change in the organization is that Asa Anderlind will be responsible for quality assurance at Enzymatica's facility in Reykjavik, Iceland. This will be in addition to her role as Director of Quality Assurance.
Exciting times ahead
All of the above will be part of Enzymatica's management team, including the two new recruits.
With the new roles and new additions in place, Enzymatica has built an organization focused on continued international growth. A reconciliation of developments will come on February 18, when the company publishes its year-end report for 2020, an event that BioStock will have reason to return to.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.